Biotech Stock Picks That Delivered Triple-digit Gains - Is There More Room To Run?
NEW YORK CITY (dpa-AFX) - As 2020 draws to a close, it s time to take a look at the top performing healthcare stocks that we profiled this year. Of the 53 stocks to which our premium subscribers have been alerted, 18 stocks have posted triple-digit gains.
What are the catalysts driving these stocks? Is there more room to run? Let s walk you through the details.
1. DermTech Inc. (DMTK)
DermTech, a commercial-stage genomics company in dermatology, was trading around $11, when we alerted our premium subscribers to it on January 19, 2020. The stock touched a high of $27.42 in intraday trading yesterday and that represents a gain of 136% from our published price.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ADPT) - The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Cardiff Oncology : Announces the Appointment of Dr Rodney Markin as Chairman of the Board
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Share this article
SAN DIEGO, Dec. 21, 2020 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that Dr. Thomas Adams has stepped down from his positions as Executive Chairman and Chairman of the Board of Directors, effective immediately. Dr. Adams will continue to serve on the Board as a Director. Dr. Rodney Markin has been appointed by the Board of Directors as the Company s new Chairman of the Board. On behalf of the entire Board, I would like to thank Tom for his leadership and dedication to the Company over the last twelve years, said Dr. Rodney Markin. Tom s contributions have enabled the Company to transition from a molecular diagnostics company and pioneer in liquid biopsy technology to a drug development company that is successfu
Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023
Financialnewsmedia.com News Commentary
PALM BEACH, Fla., Dec. 17, 2020 /PRNewswire/ Soft tissue sarcoma (STS) is a rare type of cancer that develops in tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. Generally occurring in the muscles, tissues, and blood vessels that protect, support and surround the organs. Moreover, it is not categorized as tumor, but can be life-threatening if the cancer spreads to other parts of the body. Currently, there are very few products approved for the treatment of soft tissue sarcoma, while the cases continue to increase. Industry reports say that the total number of soft tissue sarcoma patients in the seven major global markets is estimated to reach 46,864 by 2030 from 37,393 in 2019 at a CAGR of 2.0%. Increase in the incidence and prevalence of different types of cancers, rising cases of soft tissue sarcoma, increasing R&D activities on drugs and other the